Division of nuclear medicine and molecular imaging, University Hospital Leuven
Leuven, 3000, Belgium
NCT Number: NCT03514524
Alzheimer's disease, stroke and TBI are frequently observed brain disorders, causing significant morbidity. For none of these disorders, there are in vivo diagnostic biomarkers available that allow determination of disease burden, patient-specific prognosis and therapy follow-up. However, they all share a similar mechanism that may cause accumulation of tau oligomers in the brain, synaptic dysfunction and cognitive and/or behavioral impairment. Until recently, the only way to quantify synaptic density and tau deposition was using post-mortem immunohistochemistry. Now, in vivo Positron Emission Tomography (PET) imaging of synaptic density has become possible trough development of 11C-UCB-J, a levetiracetam-based radioligand, expressing high affinity and specificity for SV2A. Furthermore, the novel radioligand 18F-MK-6240, specifically targeting tau deposits, was clinically implemented in our center. Through PET-MR, we can visualize the cascade of tau deposition, synaptic loss and degeneration of grey and white matter and relate these pathologic features to cognitive and behavioral deterioration. The goal of the study is to: 1) measure tau deposition and loss of synaptic density in these conditions as a potential measure for disease load 2) determination of the mid-term (2 years) monitoring capacity of combined functional-structural PET-MR imaging 3) relate progression of the imaging markers to cognitive and/or behavioral decline and 4) determination of the optimal combination of PET-MR metrics for early identification and risk-stratification of cognitive and/or behavioral dysfunction in de novo patients.
Interested in participating?
Request Info18 year–80 year
All sexes
Interventional
Not applicable
Leuven, 3000, Belgium
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
No evidence of neurological disorder as evidenced by neurological examination No evidence of cognitive impairment as assessed by a MMSE score >= 28. In subjects < 60 years of age, an unremarkable structural MRI scan as assessed by expert radiologist. In subjects >= 60 years of age white matter hyperintensities corresponding to a WML (white matter lesion) score <= 2 (of 3) on the Age-Related White Matter changes scale are acceptable.
The volunteer is willing to undergo an additional 11C-PIB amyloid scan when cerebral amyloid status is unknown (if known, should have been performed in the year before inclusion).
Exclusion criteria
Both 18F-MK-6240 and 11C-UCB-J PET-MR will be performed at base-line (all arms) 6 months after TBI/stroke (TBI and stroke arm) and after 2 years (TBI, stroke, CTE and MCI/MBI arls)
Time frame: 2 years
11C-UCB-J PET will be used to assess this outcome measure
Time frame: 2 years
18F-MK-6240 PET will be used to assess this outcome measure
Time frame: 3 years
Mid-term monitoring capacities will be assessed by repeated imaging in a longitudinal (6 months and 2 year time point) study set-up.
Time frame: 4 years
This relationship will be assessed using an extensive neuropsychological test battery (MMSE, CANTAB, BNT, TMT, RAVLT, AVF, RCPM) and various questionnaires (BDI, GDS, SCL-90, NPI-Q) at each scanning time point.
Universitaire Ziekenhuizen KU Leuven
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03322306
Neuro-Degenerative Disease
Hong Kong, Shatin
View Trial DetailsNCT03197363
Body Weight, Cardiovascular Diseases
Bialystok, Poland
View Trial DetailsNCT06151600
Nervous System Diseases, Neuro-Degenerative Disease
San Francisco, California, United States
View Trial DetailsNCT07087574
Neuro-Degenerative Disease
Hyères, Var, France
View Trial Details